Hyperion Revealed As Andromeda’s Mystery Buyer In $570M Deal
This article was originally published in The Pink Sheet Daily
The California biotech is adding to its orphan drug roster with the purchase of the Israeli biotech and its late-stage type 1 diabetes treatment in a back-loaded deal that leaves little room for risk.
You may also be interested in...
Ravicti’s price tag is $250,000 to $290,000 per year while the upper WAC price for Valeant’s competing product Buphenyl is roughly $240,000 at the maximum dose; Hyperion has option to acquire Buphenyl.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.